Full-Time

Head of R&P

Payroll, Absence & Time Digital Product Lines

Posted on 6/24/2025

Deadline 7/24/25
Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and life-saving vaccines

No salary listed

Sant Cugat del Vallès, Barcelona, Spain

Hybrid

Hybrid position.

Category
💡Product (1)
Requirements
  • Minimum of 10 years of experience in digital product management or HR technology strategy
  • At least 5 years in a leadership role overseeing reward and performance management systems and technology portfolios
  • Extensive experience in managing the configuration of Workday’s compensation and absence modules
  • Knowledge of benefits and wellness vendor integrations
  • Experience managing interfaces with local payroll and time management systems
  • Proven leadership skills with a demonstrated ability to manage cross-functional teams through complex global technology initiatives
  • Strong collaborative skills, particularly in working with diverse stakeholders across multiple regions
  • Ability to anticipate business needs and manage technical debt while delivering on a strategic roadmap for reward and performance management
  • Excellent verbal and written communication skills
  • Experience in change management and stakeholder engagement
  • Bachelor’s degree in Business, Technology, Human Resources, or a related field
  • Advanced degree or relevant certifications in HRIS, Workday, or reward management are preferred
Responsibilities
  • Lead the product management team responsible for the global configuration and support of reward and performance solutions within the Workday tenant
  • Oversee the configuration of Workday’s compensation and advanced compensation modules
  • Manage the integration of benefits and wellness vendors with Workday
  • Lead the design and management of the core model for interfacing Workday with local payroll and time management systems
  • Drive the execution of the strategic roadmap for reward and performance digital products
  • Oversee the end-to-end process design for reward and performance management
  • Partner with Centers of Excellence (CoEs), Digital Products, People Services, and local market HR teams to ensure successful implementation and alignment of reward and performance solutions
Desired Qualifications
  • Advanced skills in Agile Mindset and Practices
  • Consumer Experience
  • Digital strategy & Governance
  • Project Management & planning

Sanofi provides healthcare solutions through the development of treatments and vaccines. The company focuses on research and development to create new therapies for conditions in immunology, oncology, and rare diseases, as well as to produce vaccines. Sanofi's products include prescription medicines and over-the-counter items, which are made available to patients, healthcare professionals, and governments. The company operates by investing in scientific research and forming partnerships to enhance its product offerings. It generates revenue from the sale of its pharmaceutical products and vaccines, along with collaborations with other healthcare organizations. What sets Sanofi apart from its competitors is its strong emphasis on R&D and its ability to navigate complex regulatory environments globally. The company aims to improve health outcomes and the quality of life for individuals by providing effective and safe healthcare solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's acquisition of Blueprint Medicines expands its portfolio in rare immunological diseases.
  • The approval of Dupixent for chronic spontaneous urticaria opens new market opportunities.
  • Sanofi's investment in Adagene supports innovative cancer treatment development.

What critics are saying

  • Large-scale acquisitions may strain Sanofi's financial stability if returns are insufficient.
  • Regulatory challenges could delay the market entry of new treatments like tolebrutinib.
  • Dependence on strategic partnerships may pose risks if collaborations don't meet expectations.

What makes Sanofi unique

  • Sanofi's extensive R&D efforts focus on unmet medical needs in immunology and oncology.
  • The company leverages strategic partnerships to enhance its product pipeline and market reach.
  • Sanofi's global presence allows it to navigate diverse regulatory environments effectively.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Investors Hangout
Jul 1st, 2025
Adagene Secures $25M Investment from Sanofi

Adagene Inc. has secured a strategic investment of up to $25 million from Sanofi to advance its research and development, particularly for the clinical trials of muzastotug (ADG126), an anti-CTLA-4 SAFEbody targeting microsatellite stable colorectal cancer. This funding will extend Adagene's operational runway into 2027 and includes a phase 2 trial with over 100 patients. The partnership also allows Sanofi a role in Adagene's Scientific Advisory Board.

Sanofi
Jun 18th, 2025
Press release: Sanofi successfully prices €1.5 billion bond issue

Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches:  €750...

PharmiWeb
Jun 3rd, 2025
Asco: New Sarclisa Data Support Subcutaneous Administration With On-Body Injector

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse ® on-body injector, an automated hands-free injectoron-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatmentParis, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa’s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.Alyssa Johnsen, MD, PhDGlobal Therapeutic Area Head, Immunology and Oncology Development“Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation that could improve and streamline the treatment process for both patients and providers. We are pleased to share these data, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forward to potentially bringing this formulation and administration option to the multiple myeloma community.”The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection.The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections’ enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa

GlobeNewswire
Jun 2nd, 2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...

Sanofi
May 23rd, 2025
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has...

INACTIVE